Americans bought additional shares of Celon Pharma
A California-based fund that invests in the biotechnology sector has purchased additional shares in Celon Pharma and exceeded the 5% threshold in the total number of votes.
The investor, who previously owned 2.7 million shares to be issued in 2024 (at a price of PLN 15 per share), increased its holdings by 1.44 million shares. Its share in the capital increased from 5.01% to 7.68%, and its voting rights from 3.92% to 6.01%.
Tang Capital is the fund of Kevin Tang, who was a biotech analyst in the 1990s and later began investing in the sector himself. He holds equity stakes in numerous American biotech companies and has also founded several companies and sold them to pharmaceutical companies. Biotech companies he has acquired include AstraZeneca, Innoviva, and Endo Pharmaceuticals.
Celon Pharma's main shareholder is CEO Maciej Wieczorek (65.39% of votes). OFe Generali also holds shares above the 5% threshold.
Tang Capital had shares of these companies in its portfolio as of March 31, 2025. Their total value reached almost USD 2 billion.
najnowsze
